References
- Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate – modifiers of lymphocyte migration. N. Engl. J. Med.355(11), 1088–1091 (2006).
- Kappos L, O’Connor P, Polman C et al. Oral fingolimod (FTY720) vs placebo in relapsing–remitting multiple sclerosis: 24-month clinical efficacy results from a randomized, double-blind, placebo-controlled, multicenter Phase III study (FREEDOMS). Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
- Radue E-W, O’Connor P, Polman C et al. Oral fingolimod (FTY720) reduces inflammatory activity vs placebo in relapsing–remitting multiple sclerosis: 24-month MRI results from a randomized, double-blind, placebo-controlled, multicenter Phase III study (FREEDOMS). Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
- Khatri B, Barkhof F, Comi G et al. 24-month efficacy and safety outcomes from the TRANSFORMS extension study of oral fingolimod (FTY720) in patients with relapsing–remitting multiple sclerosis. Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 416–426 (2010).
- Giovannoni G, Comi G, Cook S et al. Analysis of clinical and radiological disease activity-free status in patients with relapsing remitting multiple sclerosis (RRMS) treated with cladribine tablets, in the double-blind, 96-week CLARITY study. Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Martino G, Franklin RJ, Van Evercooren AB, Kerr DA. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat. Rev. Neurol.6(5), 247–255 (2010).
- Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood106(5), 1755–1761 (2005).
- Karussis D, Karageorgiou C, Gowda-Kurkalli B et al. Pilot Phase I/II clinical trial with autologous mesenchymal stem cells in patients with multiple sclerosis and amyotrophic lateral sclerosis. Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature420(6911), 78–84 (2002).
- Waubant E, Pelletier D, Mass M et al. Atorvastatin reduces the risk of new brain MRI lesions in patients with clinically isolated syndrome (CIS) compared to placebo. Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Freedman M, Wolinsky JS, Frangin GA et al. Oral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Polman C, Bowen J, Barkhof F et al. Double-blind, placebo-controlled randomized Phase II serial MRI, safety and tolerability study of two doses of CDP323 in subjects with relapsing forms of multiple sclerosis over 24 weeks. Presented at: 62nd Annual Meeting, American Academy of Neurology.Toronto, ON, Canada, 10–17 April 2010.
- Yadav V, Bourdette D, Bowen JD et al. Recombinant T cell receptor ligand (RTL) for the treatment of multiple sclerosis: report of a Phase I clinical trial. Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.
- Krupp LB, Christodoulou C, Melville P et al. A multi-center randomized clinical trial of donepezil to treat memory impairment in multiple sclerosis. Presented at: 62nd Annual Meeting, American Academy of Neurology. Toronto, ON, Canada, 10–17 April 2010.